Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.86 USD | -0.03% | +2.09% | +215.92% |
Financials (USD)
Sales 2024 * | 2.14M | Sales 2025 * | - | Capitalization | 734M |
---|---|---|---|---|---|
Net income 2024 * | -66M | Net income 2025 * | -93M | EV / Sales 2024 * | 218 x |
Net cash position 2024 * | 267M | Net cash position 2025 * | 320M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-10.1
x | P/E ratio 2025 * |
-8.26
x | Employees | 50 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.5% |
Latest transcript on Longboard Pharmaceuticals, Inc.
1 day | +5.42% | ||
1 week | +0.37% | ||
1 month | -17.27% | ||
3 months | -11.57% | ||
6 months | +371.75% | ||
Current year | +212.94% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Lind
CEO | Chief Executive Officer | 47 | 20-01-02 |
Brandi Roberts
DFI | Director of Finance/CFO | 50 | 20-12-31 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 20-11-30 |
Director/Board Member | 68 | 20-11-30 | |
Vincent Aurentz
BRD | Director/Board Member | 56 | 20-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.41% | 4 M€ | -5.15% | - | |
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 19.05 | +0.95% | 54 313 |
24-05-31 | 18.87 | +5.42% | 626,829 |
24-05-30 | 17.9 | -1.70% | 268,079 |
24-05-29 | 18.21 | -2.41% | 390,285 |
24-05-28 | 18.66 | -0.74% | 298,179 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+212.94% | 734M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- LBPH Stock